Probiotics & the microbiome- challenges and opportunities
Eran Elinav
分会场:2019中国肠道大会 - 肠道菌群与健康大会
Consumption of over-the-counter probiotics for promoting health and well-being has increased in recent years worldwide. However, although probiotics use has been greatly popularized by the general public, there are conflicting clinical results for many proposed probiotics. Emerging insights from microbiome research are allowing an assessment of gut colonization by probiotics, strain-level activity, interactions with the indigenous microbiome, safety and impacts on the host, and allow an association with physiological effects and potentially useful medical indications. In a highly invasive assessment in mice and in humans, in toth homeostatic and antibiotic-perturbation conditions, we study the impacts of the indigenous host and micobiome on probiotics colonization and effects on the host.
Eran Elinav
以色列魏茨曼研究所
Dr. Eran Elinav, M.D., Ph.D. is a professor at the Department of Immunology, Weizmann Institute of Science. His lab focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition. Dr. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a physician-scientist position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine. Dr. Elinav has published more than 120 publications in leading peer-reviewed journals, including major recent discoveries related to the effects of host genetics, innate immune function and environmental factors, such as dietary composition and timing, on the intestinal microbiome and its propensity to drive multi-factorial disease. His honors include multiple awards for academic excellence including the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine (2011), the Alon Foundation award (2012), the Rappaport prize for biomedical research (2015), the Lindner award (2016) and the Levinson award for basic science research (2016). Since 2016 he is a senior fellow at the Canadian Institute For Advanced Research (CIFAR), and since 2017 he’s an international scholar at the Howard Hughes Medical Institute (HHMI)  and the Bill & Melinda Gates Foundation.
更多视频
无菌动物及其在疾病微生物组研究中的应用
无菌动物与宏基因组技术是驱动人体健康微生物组研究的两大车轮。没有无菌动物菌群(株)移植模型,就无法确立菌群与疾病的因果关系;没有无菌动物,就没有菌群与人体疾病研究飞速发展的今天与明天。无菌动物应用已形成有菌与无菌动物比较、菌群(株)移植、基因工程动物无菌化、无菌动物发育四种通用研究模式,研究模式的标准化将加大无菌动物研究应用规模及速度。本课题组经过十余年努力,已建成国内最具影响力的无菌动物平台,为国内生物医学、畜牧、食品微生物组科学问题解决提供了有力支撑。但是,目前我国无菌动物规模小、效率低、供用平台与应用条件分离,无菌动物基础理论与技术体系尚待发展,难以满足日益增长的应用需求。亟待建立规模化无菌动物高效研究应用体系,加强无菌动物基础研究,加强无菌动物应用推广,以适应我国微生物组研究高速发展。
魏泓 时长:20:34
The Microbiome and Gastric Cancer
Gastric cancer (GC) is a common cancer in Asian, which arises due to a combination of genetic and environmental factors. Chronic inflammation with Helicobacter pylori is a major risk factor for GC. However, only about 3% of H. pylori-infected people develop GC. Changes in gastric microbial composition are associated with GC, but the role of bacteria other than H. pylori is yet to be established. We seek to characterize the microbial changes associated with histologic stages of gastric tumorigenesis. We performed 16S rRNA gene analysis of gastric mucosal samples from 81 cases including superficial gastritis (SG), atrophic gastritis (AG), intestinal metaplasia (IM) and gastric cancer (GC), to determine mucosal microbiome dysbiosis across stages of GC. We validated the results in mucosal samples of 126 cases from Inner Mongolia, China. Moreover, we identified differences in bacterial interactions across stages of gastric carcinogenesis in addition to microbial compositional changes. The significant enrichments and network centralities suggest potentially important roles of P. stomatis, D. pneumosintes, S. exigua, P. micra and S. anginosus in gastric cancer progression (Gut 2018). To identify non-H. pylori gastric microbes that are associated with inflammation, GA and IM post-treatment of H. pylori infection, we evaluated a total of 295 cases received one-week course omeprazole, amoxicillin and clarithromycin (OAC) while 292 cases received placebo. Subjects underwent endoscopy with biopsy at baseline and after one year. We demonstrated that Oral bacterial genera Peptostreptococcus, Streptococcus, Parvimonas, Prevotella and Porphyromonas are associated with the progression of gastric inflammation, GA and IM following anti-H. pylori therapy. Treatment targeting these bacteria may be prescribed to patients to reduce the risk of developing gastric cancer (unpublished data). The findings may help to provide new insights for the molecular pathogenesis of gastric carcinogenesis, the potential diagnostic bacteria markers for GC and the control of this major malignance.
于君 时长:17:25
Population-based studies for characterization of the healthy human microbiome
The Center for Translational Microbiome Research (CTMR) started in January 2016 as a collaboration between Karolinska Institutet, Science for Life Laboratory and Ferring Pharmaceuticals. Since then, a broad technical, biological, clinical and epidemiological platform for studying complex microbiological communities in well-defined human materials has been established. CTMR aims to better understand the contribution of the human microbiome to physiology and pathophysiology with the goal to open opportunities for development of novel therapies in the area of gastroenterology and reproductive health. The talk will present details on CTMR´s efforts to define what is healthy in the human gut and vaginal microbiome and approaches to develop therapies or lifestyle interventions to change a dysbiotic profile back to normal again.
Lars Engstrand 时长:21:22
评论